Evidence map›Paper›PMID 37708126›Full record

ArticlePloS one2023

Characterization of Fibrodysplasia Ossificans Progessiva relevant Acvr1/Acvr2 Activin receptors in medaka (Oryzias latipes).

Michael Trumpp, Wen Hui Tan, Wiktor Burdzinski, Yara Basler, Jerome Jatzlau, Petra Knaus, Christoph Winkler

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael TrumppInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.ORCID 0000-0002-6151-9151
Wen Hui TanDepartment of Biological Sciences and Centre for Bioimaging Sciences, National University of Singapore, Singapore, Singapore.
Wiktor BurdzinskiInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Yara BaslerInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Jerome JatzlauInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.ORCID 0000-0002-1757-0267
Petra KnausInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Christoph WinklerDepartment of Biological Sciences and Centre for Bioimaging Sciences, National University of Singapore, Singapore, Singapore.ORCID 0000-0003-4688-6241

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activin and Bone Morphogenetic Protein (BMP) signaling plays crucial roles in vertebrate organ formation, including osteo- and angiogenesis, and tissue homeostasis, such as neuronal maintenance. Activin and BMP signaling needs to be precisely controlled by restricted expression of shared receptors, stoichiometric composition of receptor-complexes and presence of regulatory proteins. A R206H mutation in the human (hs) BMP type I receptor hsACVR1, on the other hand, leads to excessive phosphorylation of Sons of mothers against decapentaplegic (SMAD) 1/5/8. This in turn causes increased inflammation and heterotopic ossification in soft tissues of patients suffering from Fibrodysplasia Ossificans Progressiva (FOP). Several animal models have been established to understand the spontaneous and progressive nature of FOP, but often have inherent limitations. The Japanese medaka (Oryzias latipes, ola) has recently emerged as popular model for bone research. To assess whether medaka is suitable as a potential FOP animal model, we determined the expression of Activin receptor type I (ACVR1) orthologs olaAcvr1 and olaAcvr1l with that of Activin type II receptors olaAcvr2ab, olaAcvr2ba and olaAcvr2bb in embryonic and adult medaka tissues by in situ hybridization. Further, we showed that Activin A binding properties are conserved in olaAcvr2, as are the mechanistic features in the GS-Box of both olaAcvr1 and olaAcvr1l. This consequently leads to FOP-typical elevated SMAD signaling when the medaka type I receptors carry the R206H equivalent FOP mutation. Together, this study therefore provides experimental groundwork needed to establish a unique medaka model to investigate mechanisms underlying FOP.

Indexed as

OryziasActivin ReceptorsActivinsAdultAnimalsCell MembraneHumansIn Situ HybridizationActivin ReceptorsActivins

Identifiers

PMID37708126
PMCPMC10501582

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.